Cargando…
Recommendations for the design of small population clinical trials
BACKGROUND: Orphan drug development faces numerous challenges, including low disease prevalence, patient population heterogeneity, and strong presence of paediatric patient populations. Consequently, clinical trials for orphan drugs are often smaller than those of non-orphan drugs, and they require...
Autores principales: | Day, Simon, Jonker, Anneliene Hechtelt, Lau, Lilian Pek Lian, Hilgers, Ralf-Dieter, Irony, Ilan, Larsson, Kristina, Roes, Kit CB, Stallard, Nigel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219020/ https://www.ncbi.nlm.nih.gov/pubmed/30400970 http://dx.doi.org/10.1186/s13023-018-0931-2 |
Ejemplares similares
-
Directions for new developments on statistical design and analysis of small population group trials
por: Hilgers, Ralf-Dieter, et al.
Publicado: (2016) -
The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases – recommendations of the IRDiRC Data Mining and Repurposing Task Force
por: Southall, Noel T, et al.
Publicado: (2019) -
How to START? Four pillars to optimally begin your orphan drug development
por: Jonker, Anneliene Hechtelt, et al.
Publicado: (2023) -
French recommendations for the management of Behçet’s disease
por: Kone-Paut, Isabelle, et al.
Publicado: (2021) -
French recommendations for the management of systemic sclerosis
por: Hachulla, Eric, et al.
Publicado: (2021)